Atrial fibrillation (AF) is a common heart condition that affects about one in three people at some point in their lives. It ...

At McLeod Regional Medical Center, McLeod Electrophysiologists Dr. Prabal Guha and Dr. Cyrus Kocherla are performing safe and successful ablations in patients using the new FDA-approved pulsed field ...

Patients with a common heart rhythm disorder who took an experimental blood-thinning drug had far fewer bleeding episodes ...

A new study highlights that the experimental blood-thinner abelacimab significantly reduces bleeding risks in atrial fibrillation patients compared to standard treatments like rivaroxaban. In trial ...

Use of smokeless tobacco, cigars, and pipes increased the risk for coronary heart disease and heart attacks, according to a ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than ...

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making significant strides in recent years, positioning itself as a frontrunner in the industry.

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Three common heart conditions—heart failure, atrial fibrillation, and coronary heart disease—are closely linked to cognitive decline and a higher risk of dementia, according to a new scientific ...

That's significant because the GI tract is the most common site of bleeding with DOACs, and this type of bleeding is the only one for which DOACs do not have a better risk profile ...

Dr. Ron Aviles explains available procedures and recovery time for those with heart and vascular conditions. Sponsored by Overlake Medical Center and Clinics.

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...